Document is current

Article History

Received: 11 October 2023

Accepted: 30 July 2024

First Online: 16 September 2024

Change Date: 17 October 2024

Change Type: Update

Change Details: In the original publication there was a typo in the article title. The article has been updated to rectify the error.

Declarations

:

: This study was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments. For the MindLinc EHR, institutional review board (IRB) approval for this study was not required because MindLinc data are anonymized and thus exempt from Health Insurance Portability and Accountability Act requirements. The NeuroBlu Database platform received a waiver of informed consent prior to study conduct from the WCG Institutional Review Board (Ref: The Holmusk Real-World Evidence Parent Protocol; IRB registration number 1-1470336-1; Protocol ID HolmuskRWE_1.0).

: Not applicable.

: At the time of this study CL, AW, XH, and ST report employment with Holmusk Technologies, Inc; JS reports employment with Otsuka Pharmaceutical Development & Commercialization Inc; SB was previously an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. when the study took place; SK reports previous employment with Holmusk Technologies Inc, as well as current employment with Aura and is an adjunct faculty member in the Department of Psychiatry of Duke University School of Medicine; AC received research grants and/or consulting fees from Aardvark, Adlon, Akili, Cingulate, Axial, Axsome, Acadia, Cingulate, Emalex, Otsuka, Lumos, Neurocentria, Sunovion, Supernus, Corium, Purdue, Takeda, and Kempharm, is a consultant/advisor for Attentive, Atyu, Cingulate, Otsuka, Lumos, Neurocentria, Supernus, Corium, Kempharm, Noven, Tris, Tulex, and Sky, and is a speaker for Supernus, Takeda, Tris, Ironshore and Corium. She has received writing support from Takeda, Corium, Noven, Otsuka, and Purdue.